insulin

The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: SNY) Genzyme Corporation. SNY is demonstrating bullish strength. Check out the latest moves...

Embecta Corp (NASDAQ:EMBC), a manufacturer of disposable insulin pen needles and syringes, is considering a potential sale following a significant drop in its share price since being spun off from health tech giant Becton, Dickinson and Company (NYSE:BDX). The medical technology company, which...

The House of Representatives voted to approve legislation that would limit cost-sharing for insulin under private health insurance and Medicare.  The vote was 232 (yes)-193 (no), with 12 Republican members joining their Democratic colleagues to pass the measure. The Affordable...

Novo Nordisk A/S (NYSE: NVO) has agreed to pay $100 million to settle a 2017 investor suit that alleged the Company failed to disclose that it was under the same pricing pressures as its competitors. Related Content: House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On...

House Energy & Commerce Committee leaders sent three letters to execs at Eli Lilly And Co (NYSE: LLY), Sanofi SA (NASDAQ: SNY), and Novo Nordisk A/S (NYSE: NVO), raising concerns that despite their supposed concern over the past two years with the price...

The FDA has approved the use of Eli Lilly And Co's (NYSE: LLY) Lyumjev (insulin lispro-aabc injection) 100 units/mL with Insulet Corporation's (NASDAQ: PODD) insulin management systems. Lyumjev, approved by the FDA in June 2020, is a formulation of insulin...

The FDA cleared Viatris inc (NASDAQ: VTRS) - Biocon Biologics' Semglee insulin glargine-yfgn injection as a biosimilar. Semglee indicates controlling high blood sugar in adults with type 2 diabetes and pediatric patients with type 1 diabetes.  The FDA approved Semglee...

Eli Lilly And Co (NYSE: LLY) CEO David Ricks said he welcomes new competition from Walmart Inc (NYSE: WMT) even as the retailer undercuts the company's insulin prices. Walmart announced Tuesday is launching its first-ever private label insulin analog, available exclusively...

Walmart Inc (NYSE: WMT) is launching its first-ever private label insulin analog, available exclusively at its stores. The company worked directly with manufacturer Novo Nordisk A/S (NYSE: NVO) on ReliOn Novolog, allowing it to offer the product in both vials and FlexPens at a...

Sanofi SA (NASDAQ: SNY) has announced new study data of Soliqua 100/33 (insulin glargine and lixisenatide injection) that met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed insulin in type 2 diabetes. The data were presented...

Eli Lilly And Co (NYSE: LLY) CEO David Ricks said Tuesday that U.S. Sen. Elizabeth Warren’s criticism of the cost of the drugmaker's insulin is “nonsense.” Warren Says Eli Lilly Broke Promise On Insulin In a Monday Facebook post, the Democratic presidential candidate denounced...

Tandem Diabetes Care Inc (NASDAQ: TNDM) shares traded lower Friday after a report of the death of a patient using Tandem’s T:SLIM X2 insulin pump was added to the Food and Drug Administration’s Adverse Event report system. The report said the patient’s blood glucose was low at the...

Valeritas Holdings Inc (NASDAQ: VLRX), a medical technology company known for its V-Go Wearable Insulin Delivery device, could more than double in value, according to Oppenheimer. The Analyst Oppenheimer's Steven Lichtman initiated coverage of Valeritas with an Outperform rating and 12- to 18-...

Raymond James identified four major tailwinds for Insulet Corporation (NASDAQ: PODD) that the firm said could help drive 20-percent-plus revenue growth over the next two years. The Analyst Raymond James analyst Jayson Bedford upgraded Insulet from Market Perform from Outperform with an $80...

Despite a more than 200-percent gain in MannKind Corporation (NASDAQ: MNKD)'s stock over the past month alone analysts at H.C. Wainwright see even further upside ahead. The firm's Oren Livnat initiates coverage of MannKind's stock with a Buy rating and $7 price target, which represents a gain of...